Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010247 | 0.90 | SMN1; SMN2 (0.69) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL469448 | 0.85 | SMN1; SMN2 (0.71) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL3990399 | 0.83 | SMN1; SMN2 (0.60) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL7141238 | 0.83 | ALDH1A1 (0.60) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL7982548 | 0.82 | SMN1; SMN2 (0.64) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL469451 | 0.82 | SMN1; SMN2 (0.67) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL469454 | 0.82 | SMN1; SMN2 (0.67) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL2605749 | 0.81 | KMT2A (0.63) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL19027028 | 0.81 | SMN1; SMN2 (0.58) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL469447 | 0.81 | SMN1; SMN2 (0.65) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709310-A | Substituted cyclic amides and its purposes as herbicide | 杜邦公司 | 2018-02-16 | — | — | CN | disclosed |
| CN-107001260-A | 3 epoxide 3 (fragrant amino) propionic esters, its preparation method and its purposes in pyrrolidones is prepared | 杜邦公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| US-9527805-B2 | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-27 | — | — | US | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-8759522-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-06-24 | — | — | US | disclosed |
| US-8759522-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-06-24 | — | — | US | disclosed |
| US-8729268-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-05-20 | — | — | US | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| CN-101796055-A | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC | 2010-08-04 | — | — | CN | disclosed |
| EP-1957498-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | MethylGene Inc. (CA) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | PTK2B, PRKACA, DSTYK | NPC1 4018/4885SMN1; SMN2 3148/4885RAB9A 1569/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | NPC1 1129/4885SMN1; SMN2 4550/4885RAB9A 2065/4885 |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | ABL1, ERBB2, TYRO3 | NPC1 3651/4885SMN1; SMN2 4292/4885RAB9A 2229/4885 |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ABL1, ERBB2, TYRO3 | NPC1 3651/4885SMN1; SMN2 4292/4885RAB9A 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.